IL4 and glioblastoma: A multicenter, randomized, open-label phase II study with IL-4(38-37)-PE38KDEL administered to recurrent GBM patients was conducted to evaluate the efficacy, safety, and tolerability of the toxin after continuous intratumoral infusion of the toxin at total doses of up to 90 μg followed by surgical resection of the tumor [44].